UBS lowered its price target on Johnson & Johnson (NYSE: JNJ) to $141.00 (from $142.00) while maintaining a Buy rating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Johnson & Johnson (JNJ) PT Lowered to $115 at Goldman Sachs, Says Response On Drug Prices Was Underwhelming January 25, 2017 3:14 AM J&J Exit from Diabetes Seen Positive for (TNDM), (PODD) and (MDT) and Slight Negative for DexCom (DXCM) - WedbushJanuary 24, 2017 12:42 PM Things Said to Move Ahead with Actelion (ALIOY) /Johnson & Johnson (JNJ) - CNBC's Faber January 24, 2017 9:35 AM Pre-Open Stock Movers 01/24: (MPSX) (IIVI) (AKS) Higher; (FSM) (OCUL) (VZ) Lower (more...)January 24, 2017 9:28 AM 2016 Industry Pressures Drive Mixed Healthcare Investor Sentiment in 4th QuarterJanuary 24, 2017 8:00 AM Johnson & Johnson plans more price transparency; eyes U.S. tax, healthcare changesJanuary 24, 2017 6:53 AM Johnson & Johnson (JNJ) Tops Q4 EPS by 2c; Guides Modestly Below the StreetJanuary 24, 2017 6:42 AM Johnson & Johnson Reports 2016 Fourth-Quarter Results:January 24, 2017 6:40 AM Johnson & Johnson to Participate in the Leerink Partners 6th Annual Global Healthcare ConferenceJanuary 23, 2017 10:46 AM The ECHELON FLEX™ GST System Will Now Feature A 45mm Endocutter With Exclusive Gripping Surface Technology ReloadsJanuary 23, 2017 8:30 AM